314 related articles for article (PubMed ID: 33883011)
1. Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease.
Zerr I; Villar-Piqué A; Hermann P; Schmitz M; Varges D; Ferrer I; Riggert J; Zetterberg H; Blennow K; Llorens F
Alzheimers Res Ther; 2021 Apr; 13(1):86. PubMed ID: 33883011
[TBL] [Abstract][Full Text] [Related]
2. The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias.
Abu-Rumeileh S; Capellari S; Stanzani-Maserati M; Polischi B; Martinelli P; Caroppo P; Ladogana A; Parchi P
Alzheimers Res Ther; 2018 Jan; 10(1):3. PubMed ID: 29368621
[TBL] [Abstract][Full Text] [Related]
3. Blood Neurofilament Light Chain in Different Types of Dementia.
Gu L; Shu H; Wang Y; Wang P
Curr Alzheimer Res; 2023; 20(3):149-160. PubMed ID: 37264656
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: Evaluation of diagnostic accuracy in the differential diagnosis of prion diseases.
Zerr I; Schmitz M; Karch A; Villar-Piqué A; Kanata E; Golanska E; Díaz-Lucena D; Karsanidou A; Hermann P; Knipper T; Goebel S; Varges D; Sklaviadis T; Sikorska B; Liberski PP; Santana I; Ferrer I; Zetterberg H; Blennow K; Calero O; Calero M; Ladogana A; Sánchez-Valle R; Baldeiras I; Llorens F
Alzheimers Dement; 2018 Jun; 14(6):751-763. PubMed ID: 29391125
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic and prognostic value of cerebrospinal fluid SNAP-25 and neurogranin in Creutzfeldt-Jakob disease in a clinical setting cohort of rapidly progressive dementias.
Bentivenga GM; Baiardi S; Mastrangelo A; Zenesini C; Mammana A; Polischi B; Capellari S; Parchi P
Alzheimers Res Ther; 2023 Sep; 15(1):150. PubMed ID: 37684653
[TBL] [Abstract][Full Text] [Related]
6. CSF neurogranin as a neuronal damage marker in CJD: a comparative study with AD.
Blennow K; Diaz-Lucena D; Zetterberg H; Villar-Pique A; Karch A; Vidal E; Hermann P; Schmitz M; Ferrer Abizanda I; Zerr I; Llorens F
J Neurol Neurosurg Psychiatry; 2019 Aug; 90(8):846-853. PubMed ID: 31097472
[TBL] [Abstract][Full Text] [Related]
7. Comparison between plasma and cerebrospinal fluid biomarkers for the early diagnosis and association with survival in prion disease.
Abu-Rumeileh S; Baiardi S; Ladogana A; Zenesini C; Bartoletti-Stella A; Poleggi A; Mammana A; Polischi B; Pocchiari M; Capellari S; Parchi P
J Neurol Neurosurg Psychiatry; 2020 Nov; 91(11):1181-1188. PubMed ID: 32928934
[TBL] [Abstract][Full Text] [Related]
8. Total and Phosphorylated Cerebrospinal Fluid Tau in the Differential Diagnosis of Sporadic Creutzfeldt-Jakob Disease and Rapidly Progressive Alzheimer's Disease.
Hermann P; Haller P; Goebel S; Bunck T; Schmidt C; Wiltfang J; Zerr I
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215868
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias.
Baiardi S; Quadalti C; Mammana A; Dellavalle S; Zenesini C; Sambati L; Pantieri R; Polischi B; Romano L; Suffritti M; Bentivenga GM; Randi V; Stanzani-Maserati M; Capellari S; Parchi P
Alzheimers Res Ther; 2022 Oct; 14(1):153. PubMed ID: 36221099
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and Prognostic Value of Plasma GFAP in Sporadic Creutzfeldt-Jakob Disease in the Clinical Setting of Rapidly Progressive Dementia.
Bentivenga GM; Baiardi S; Mastrangelo A; Zenesini C; Mammana A; Rossi M; Polischi B; Capellari S; Parchi P
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791145
[TBL] [Abstract][Full Text] [Related]
11. NT1-Tau Is Increased in CSF and Plasma of CJD Patients, and Correlates with Disease Progression.
Mengel D; Mok TH; Nihat A; Liu W; Rissman RA; Galasko D; Zetterberg H; Mead S; Collinge J; Walsh DM
Cells; 2021 Dec; 10(12):. PubMed ID: 34944022
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings.
Eratne D; Loi SM; Li QX; Stehmann C; Malpas CB; Santillo A; Janelidze S; Cadwallader C; Walia N; Ney B; Lewis V; Senesi M; Fowler C; McGlade A; Varghese S; Ravanfar P; Kelso W; Farrand S; Keem M; Kang M; Goh AMY; Dhiman K; Gupta V; Watson R; Yassi N; Kaylor-Hughes C; Kanaan R; Perucca P; Dobson H; Vivash L; Ali R; O'Brien TJ; Hansson O; Zetterberg H; Blennow K; Walterfang M; Masters CL; Berkovic SF; Collins S; Velakoulis D;
Alzheimers Dement; 2022 Nov; 18(11):2218-2233. PubMed ID: 35102694
[TBL] [Abstract][Full Text] [Related]
13. Plasma total prion protein as a potential biomarker for neurodegenerative dementia: diagnostic accuracy in the spectrum of prion diseases.
Llorens F; Villar-Piqué A; Schmitz M; Diaz-Lucena D; Wohlhage M; Hermann P; Goebel S; Schmidt I; Glatzel M; Hauw JJ; Sikorska B; Liberski PP; Riggert J; Ferrer I; Zerr I
Neuropathol Appl Neurobiol; 2020 Apr; 46(3):240-254. PubMed ID: 31216593
[TBL] [Abstract][Full Text] [Related]
14. Stratification by Genetic and Demographic Characteristics Improves Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers in Rapidly Progressive Dementia.
Karch A; Llorens F; Schmitz M; Arora AS; Zafar S; Lange P; Schmidt C; Zerr I
J Alzheimers Dis; 2016 Oct; 54(4):1385-1393. PubMed ID: 27589519
[TBL] [Abstract][Full Text] [Related]
15. A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias.
Bolsewig K; Hok-A-Hin YS; Sepe FN; Boonkamp L; Jacobs D; Bellomo G; Paoletti FP; Vanmechelen E; Teunissen CE; Parnetti L; Willemse EAJ
J Alzheimers Dis; 2022; 90(1):363-380. PubMed ID: 36120776
[TBL] [Abstract][Full Text] [Related]
16. Plasma YKL-40 in the spectrum of neurodegenerative dementia.
Villar-Piqué A; Schmitz M; Hermann P; Goebel S; Bunck T; Varges D; Ferrer I; Riggert J; Llorens F; Zerr I
J Neuroinflammation; 2019 Jul; 16(1):145. PubMed ID: 31299989
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic.
Paterson RW; Slattery CF; Poole T; Nicholas JM; Magdalinou NK; Toombs J; Chapman MD; Lunn MP; Heslegrave AJ; Foiani MS; Weston PSJ; Keshavan A; Rohrer JD; Rossor MN; Warren JD; Mummery CJ; Blennow K; Fox NC; Zetterberg H; Schott JM
Alzheimers Res Ther; 2018 Mar; 10(1):32. PubMed ID: 29558979
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish Mortality Registry.
Skillbäck T; Rosén C; Asztely F; Mattsson N; Blennow K; Zetterberg H
JAMA Neurol; 2014 Apr; 71(4):476-83. PubMed ID: 24566866
[TBL] [Abstract][Full Text] [Related]
19. Validation of Plasma and CSF Neurofilament Light Chain as an Early Marker for Sporadic Creutzfeldt-Jakob Disease.
Schmitz M; Canaslan S; Espinosa JC; Fernández-Borges N; Villar-Piqué A; Llorens F; Varges D; Maass F; Torres JM; Hermann P; Zerr I
Mol Neurobiol; 2022 Sep; 59(9):1-9. PubMed ID: 35716271
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of surrogate CSF biomarkers for Creutzfeldt-Jakob disease in the era of RT-QuIC.
Abu-Rumeileh S; Baiardi S; Polischi B; Mammana A; Franceschini A; Green A; Capellari S; Parchi P
J Neurol; 2019 Dec; 266(12):3136-3143. PubMed ID: 31541342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
